Phase 3 Clinical Trials With Primary Completion Dates in August 2023

This is a list of Phase 3 trials with primary completion dates in August 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ACADACADIA Pharmaceuticals Inc.2023-08-01Phase 3NCT03623321Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
ALVOAlvotech2023-08-01Phase 3NCT05155293Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
BVNRYBavarian Nordic A/S2023-08-01Phase 3NCT02977715IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo
CBAYCymaBay Therapeutics, Inc.2023-08-01Phase 3NCT04620733RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
DNLIDenali Therapeutics Inc.2023-08-01Phase 3NCT05418673A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
ITCIIntra-Cellular Therapies, Inc.2023-08-01Phase 3NCT04985942Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
LIANLianBio2023-08-01Phase 3NCT05629390Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study
MNKDMannKind Corporation2023-08-01Phase 3NCT04974528Afrezza® INHALE-1 Study in Pediatrics
NAVBNavidea Biopharmaceuticals, Inc.2023-08-01Phase 3NCT05246280Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
NBIXNeurocrine Biosciences, Inc.2023-08-01Phase 3NCT04490915Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
SLNOSoleno Therapeutics, Inc.2023-08-01Phase 3NCT03714373Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
TVTXTravere Therapeutics, Inc.2023-08-01Phase 3NCT03762850A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy